scholarly journals Ischemic Colitis after Weight-Loss Medication

2003 ◽  
Vol 17 (12) ◽  
pp. 719-721 ◽  
Author(s):  
Dan Comay ◽  
Jennifer Ramsay ◽  
E Jan Irvine

BACKGROUND: Previous weight-loss medications have received cautious support due to their association with pulmonary hypertension and valvular heart disease. However, newer drugs are increasingly being recommended as potentially safer and more efficacious. We report a case of ischemic colitis possibly linked to the use of a weight-loss drug, and review the literature to highlight an important latent consequence of these medications.CASE REPORT: A 59-year-old obese woman presented to the emergency room with rectal bleeding and suprapubic abdominal pain. Her medical history was unremarkable for risk factors for bowel ischemia. An appetite suppressant, phentermine 15 mg daily, had been prescribed, and had resulted in a 12 kg weight loss over 10 weeks. Colonoscopy and biopsies both demonstrated findings typical of mild ischemia at the splenic flexure.DISCUSSION: Phentermine, an amphetamine-derived sympathomimetic, acts centrally to suppress appetite. While there are no published reports linking the use of phentermine as a single agent to ischemic colitis, phentermine alone has been associated with ischemic neurological events and, when used in combination with fenfluramine, has been implicated in a single case of acute ischemic colitis. Other sympathomimetics, such as cocaine, have been clearly linked with ischemic colitis.CONCLUSIONS: This report describes a temporal association with the use of phentermine and the development of ischemic colitis. Heightened awareness and appropriate surveillance is warranted to determine whether the use of weight-loss drugs, such as phentermine, can lead to ischemic colitis.

2004 ◽  
Vol 115 (1) ◽  
pp. 38-58 ◽  
Author(s):  
Holly R. Wyatt ◽  
James O. Hill

2018 ◽  
Vol 14 (1) ◽  
pp. 93-98 ◽  
Author(s):  
Zubaidah Nor Hanipah ◽  
Elie C. Nasr ◽  
Emre Bucak ◽  
Philip R. Schauer ◽  
Ali Aminian ◽  
...  

2021 ◽  
Vol 74 (7) ◽  
pp. 1617-1621
Author(s):  
Vadym P. Shypulin ◽  
Oleksandr A. Martynchuk ◽  
Nikolai N. Rudenko ◽  
Aleksandr K. Koliada ◽  
Viktoriia V. Tishchenko ◽  
...  

The aim: To study the association between the effectiveness of treatment with pioglitazone non-alcoholic fatty liver disease (NAFLD) in patients with obesity and PPARG rs1801282 (Pro12Ala)-polymorphism in Ukrainians. Materials and methods: 123 patients with NAFLD in combination with obesity 1, 2, 3 classes were included in comprehensive weight loss program (5 visits, 12-weeks). The case group was treated with pioglitazone 15 mg / day, while the control group received only program. Ultrasound (US) steatometry and genetic testing rs1801282 polymorphism in PPARG gene were performed. Results: Pioglitazone, PPARG rs1801282 genotype, CAP before treatment, previous weight loss attempts, and duration of obesity were associated with the change in controlled attenuation parameter (CAP) during treatment. There was a significant association between the target CAP reduction achievement and pioglitazone treatment (adjusted odds ratio 0.23, 95% CI 0.07–0.73; p = 0.01) with the CC genotype of PPARG gene (adjusted odds ratio 92.9, 95% CI 7.4–1159; p < 0.001) compared to patients with the CG genotype. Conclusions: Pioglitazone and PPARG rs1801282 polymorphism could influence on dynamics of CAP reduction during treatment.


2020 ◽  
Vol 51 (11) ◽  
pp. 1067-1075 ◽  
Author(s):  
Gursimran S. Kochhar ◽  
Aakash Desai ◽  
Aslam Syed ◽  
Abhinav Grover ◽  
Sandra El Hachem ◽  
...  

Appetite ◽  
2020 ◽  
Vol 150 ◽  
pp. 104650
Author(s):  
Faranak Halali ◽  
Anja Lapveteläinen ◽  
Leila Karhunen ◽  
Teuvo Kantanen

2017 ◽  
Vol 13 (3) ◽  
pp. 491-500 ◽  
Author(s):  
Fatima Cody Stanford ◽  
Nasreen Alfaris ◽  
Gricelda Gomez ◽  
Elizabeth T. Ricks ◽  
Alpana P. Shukla ◽  
...  

2006 ◽  
Vol 12 (3) ◽  
pp. 85
Author(s):  
Lynette Evans ◽  
Lisa Meehan

The objective of this study was to assess whether body dissatisfaction predicted weight loss in terms of an inverted U relationship. It was predicted that women with high and low body dissatisfaction were less likely to lose weight than women with moderate levels of body dissatisfaction. The study also sought to determine if the number of weight loss attempts, success at past weight loss and self-concept predicted percentage of weight loss in women at six months; and to test whether weight loss led to decreased body dissatisfaction and increased self-concept. Women attempting to lose weight (n = 209) were asked to complete a set of questionnaires at two time points. Results show that women with moderate scores on body dissatisfaction lost more weight than women with higher or lower scores, although this association disappeared when Body Mass Index (BMI) was controlled for in the analyses. Low BMI, success of previous weight loss and low personal self-concept predicted weight loss six months later. Women who lost weight reported lower body dissatisfaction and improved self-concept. It was concluded that, assessing for body dissatisfaction, BMI and weight loss history in the context of primary health settings, may aid in identifying women able to motivate themselves to successfully lose weight in a self-directed manner.


Sign in / Sign up

Export Citation Format

Share Document